Nicorandil Boosts Heart Failure Exercise Capacity
A study finds that oral nicorandil improves walking distance and coronary blood flow in heart failure patients.
Updated on Oct. 30, 2026 in Heart Disease
Live Poll
Do you believe clinical study results significantly influence your personal approach to managing long-term health conditions?
Researchers report that daily nicorandil treatment significantly improves exercise capacity and coronary flow in patients with heart failure with preserved ejection fraction. The intervention specifically targets those suffering from coronary microvascular dysfunction.
Why it matters
The findings suggest a potential new therapeutic avenue for managing microvascular dysfunction, a condition that currently limits exercise tolerance in heart failure patients. Validating these results through broader trials could shift standard care protocols.
In a 113-patient trial, the nicorandil group showed a mean coronary flow reserve of 2.10 compared to 1.85 in the control group over 24 months. Participants received 5 mg of the drug three times daily.
The details
The trial involved 113 patients split between an oral nicorandil regimen combined with usual treatment and a group receiving usual treatment alone. Researchers utilized the 6-minute walk distance test to quantify improvements in exercise capacity throughout the 24-month study period.
Timeline
24 months was the duration of patient follow-up and the final assessment period for the trial.
Health Landscape
This research contributes to the ongoing investigation into the assessment of coronary microvascular dysfunction in heart failure. It represents a shift toward targeted therapies for patients who previously had limited options for improving their physical performance.
The study suggests that targeted medical management could improve the daily physical mobility of patients suffering from specific forms of heart failure. Patients should consult their cardiologists regarding the potential suitability of new research-backed treatments for their condition.
The takeaway
Patients with preserved ejection fraction heart failure may see improved quality of life if these findings are confirmed in larger populations. Clinicians and patients should discuss the risks and potential benefits of medication adjustments as new data emerges.
Further reading
For more information on current treatment standards, visit Heart Disease.
Source note: This article includes information reported by European Medical Journal.
Live Poll
Do you believe clinical study results significantly influence your personal approach to managing long-term health conditions?
